A recent and interesting study reported improved respiratory activity after intravenous administration of mesenchymal stem cells (MSCs) into patients affected by coronavirus disease 2019 (COVID-19). These outcomes displayed that intravenous infiltration of MSCs is a safe and efficacy treatment for COVID-19 pneumonia, a severe acute respiratory illness caused by the coronavirus 2 (SARS-CoV-2). Only 7 patients were treated, but with extraordinary results, opening a new strategy in COVID-19 therapy. Currently, no specific therapies against SARS-CoV-2 are available. The MSCs therapy outcomes reported, are striking, as these cells inhibit the over-activation of the immune system, promoting endogenous repair, by improving the lung microenvironment after the SARS-CoV-2 infection. The MSCs could represent an effective, autologous and safe therapy, and therefore, sharing these published results, here is reported the potential use possibilities in COVID-19 of the most common MSCs represented by Adipose Stem Cells (ASCs).
【저자키워드】 COVID-19, coronavirus, Mesenchymal stem cells, adipose derived stem cells, Adipocyte secreted exosomal microRNA, 【초록키워드】 coronavirus disease, SARS-CoV-2, Efficacy, therapy, Pneumonia, Infection, lung, MSCs, immune system, outcome, Patient, infiltration, administration, MSC, Safe, intravenous, stem cell, acute respiratory illness, microenvironment, respiratory activity, effective, autologous, STEM, affected, caused, reported, inhibit, treated, these cell, endogenous repair, MSCs therapy, the SARS-CoV-2, treatment for COVID-19, 【제목키워드】 STEM, Potential,